Vaccines approved for invasive pneumococcal disease and meningococcal disease

Article

Pfizer's pneumococcal 13-variant conjugate vaccine (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes.

Pfizer's pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) (Prevnar 13) was approved by the FDA for active immunization of children aged 6 weeks through 5 years for the prevention of invasive disease caused by 13 Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. The vaccine was also approved for the prevention of otitis media caused by serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F.

Novartis received approval from the FDA for a meningococcal (groups A, C, Y, and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine (Menveo) for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitides serogroups A, C, Y, and W-135 in patients aged 11 to 55 years.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Recent Videos
Lori Handy, MD on importance of vaccine catch-up before the school year | Image credit: CHOP
Richard Wong, DO, explains challenges children with asthma face in school
Infectious Insights | Image Credit: Contemporary Pediatrics
John Browning, MD, provides practical skincare reminders ahead of summer season
Potential downstream benefits of RSV preventive measures, with Octavio Ramilo, MD
Discussing phase 3 data of Panzyga for PANS, with Michael Daines, MD
Contemporary Pediatrics: RX Review: Updates and Unmet Need in RSV thumbnail
© 2025 MJH Life Sciences

All rights reserved.